ClinicalTrialsFinder

Somatostatin Receptor Positive (SSTR+) Clinical Trials in Beijing

1 recruitingBeijing, China

Showing 1–1 of 1 trials

Recruiting
Phase 3

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

Somatostatin Receptor Positive (SSTR+)Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Novartis Pharmaceuticals240 enrolled65 locationsNCT06784752